Study on the prevalence of Zolpidem consumption in young people aged 15 to 24 in Cascavel – PR
DOI:
https://doi.org/10.33448/rsd-v13i11.47427Keywords:
Zolpidem; Insomnia; Sleep; Pharmacy.Abstract
Zolpidem is a hypnotic drug prescribed for the treatment of insomnia, with a rapid onset of action, promoting sleep in approximately 15 to 30 minutes after administration. Although effective, Zolpidem is not free from adverse effects. However, the abusive use of Zolpidem represents a significant concern since prolonged use or in doses higher than those prescribed can cause dependence. In this context, this study aimed to evaluate the prevalence of Zolpidem consumption among young people aged 15 to 24 years in Cascavel, PR. The methodological design followed a retrospective cross-sectional study, in which data from sales records of the drug Zolpidem were evaluated for young people aged 15 to 24 years, of both sexes, by a private commercial pharmacy located in Cascavel-PR. Thus, it was possible to infer the profile of Zolpidem consumption in this age group and region, with Zolpidem consumption being more prevalent among middle-aged adults, with a significantly lower demand among young people and elderly people over 80 years of age. In addition, there was a variation between 5 mg, 6.25 mg, 10 mg, and 12.5 mg, with a predominant concentration of Zolpidem among individuals, with the 10 mg dose being widely used more than the others. The results show the importance of establishing control and awareness-raising actions by health authorities, as providing valuable information to guide public health policies and educational interventions to prevent the misuse of Zolpidem.
References
Al-Dhubiab, B. E. (2016). In vitro and in vivo evaluation of nano-based films for buccal delivery of zolpidem. Brazilian Oral Research, 30(1), e126.
Anvisa. (2024). Agência Nacional de Vigilância Sanitária. Medicamento zolpidem terá alteração no tipo de receita para prescrição e venda. https://bit.ly/4eU5831.
Azevedo, B. O., dos Santos, E. F., Lima, G. S., Pujol, J. T., Antunes, A. A., & Jesus, L. O. P. (2022). Perfil farmacoterapêutico do Zolpidem. Revista Brasileira de Ciências Biomédicas, 3(1), E0642022-1.
Bouchette, D., Akhondi, H., & Quick, J. (2022). Zolpidem. 2022 Jan 19. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
Brasil. (1998). Portaria Federal Nº 344, de 12 de maio de 1998. Aprova o Regulamento Técnico sobre substâncias e medicamentos sujeitos a controle especial. Ministério da Saúde. Diário Oficial da União.
Cruz, A. F. M. (2016). Pesquisa de Novos Fármacos Hipnóticos Alternativos às Benzodiazepinas. (Master's thesis, Universidade Fernando Pessoa, Portugal.
Del Fiol, F. D. S., Bergamaschi, C. D. C., Lopes, L. C., Silva, M. T., & Barberato-Filho, S. (2023). Sales trends of psychotropic drugs in the COVID-19 pandemic: a national database study in Brazil. Frontiers in Pharmacology, 14, 1131357.
Edinoff, A. N., Wu, N. W., Ghaffar, Y. Y., Prejean, R., Gremillion, R., Cogburn, M., ... & Kaye, A. D. (2021). Zolpidem: efficacy and side effects for insomnia. Health psychology research, 9 (1):24927. Doi: 10.52965/001c.24927.
Espinosa, J., Alvarez, P. A., Castro, V., Caceres, M. F., Soler-Riera, M. C., & Bril, F. (2020). Central nervous system depressants and risk of hospitalization due to community-acquired pneumonia in very old patients. Current drug safety, 15 (2), 131-136.
Figueiró, L. D. A. P., Amaral, M. C. P., Cani, L. N., Carvalho, M. C. S., & Almeida, V. O. (2024). Principais riscos do abuso e dependência de zolpidem em pacientes com insônia. Research, Society and Development, 13 (5), e3213545736-e3213545736.
Gao, Feng, & Wu, Yujia. (2023). Procedural sedation in pediatric dentistry: a narrative review. Frontiers in Medicine. 10, 1186823.
Leal, R. P., Miranda, L. R., & Santos, G. B. (2024). Riscos da automedicação em jovens com insônia. Research, Society and Development, 13 (9), e7313946721-e7313946721.
Brasil. (2024). Saúde do Adolescente. Ministério da Saúde. Brasil. https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/s/saude-do-adolescente.
Mota, K. G., de Oliveira Sá, R., & Rosa, E. C. C. C. (2024). Estudo sobre o uso indiscriminado de zolpidem por mulheres de 20 à 40 anos no período de pandemia no Brasil (farmácia). Repositório Institucional, 2(2). https://revistas.icesp.br/index.php/Real/article/view/4963.
Moshfeghinia, R., Jazi, K., Kabaranzadghadim, S., Malekpour, M., & Oji, B. (2023). Severe chronic abuse of zolpidem for over 10 years: a case report and review of similar cases. Frontiers in Psychiatry, 14, 1252397.
Opaleye, E. S.; Noto, A. R.; Locatelli, D. P.; Castro Amato, T.; Bedendo, A. (2021). II Relatório Brasileiro sobre Drogas. 49p. Brasília: Ministério da Justiça e Segurança Pública, Secretaria Nacional de Políticas sobre Drogas.
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Santa Maria/RS. Ed. UAB/NTE/UFSM.
Ribeiro, R. M., & Ferreira, J. S. (2024). Ficha técnica Zolpidem. https://bit.ly/4f3turi.
Santos Junior, C. M., de Souza, J. I., Machado, K. V., Ferraz, L. D., & Rocha, M. P. (2023). Zolpidem: aumento do seu uso associado ao cenário pandêmico da Covid-19. Brazilian Journal of Implantology and Health Sciences, 5 (3), 955-82.
Silva, L. A. T., Soliani, F. C. D. B. G., & Sanches, A. C. S. (2022). Hipnóticos-z no tratamento da insônia. Revista Neurociências, 30, 1-17.
Suassuna, C. A., Guará, P. T., Rangel, L. D. O. B., Regis, R. C., Tafuri, G. B., & de Oliveira, P. D. (2023). Impactos relacionados ao aumento do uso abusivo e prolongado de zolpidem. Revista Ibero-Americana de Humanidades, Ciências e Educação, 1 (2), 280-9.
Yoon, K., Kim, J. T., Kwack, W. G., Kim, D., Lee, K. T., Yang, S., ... & Chung, E. K. (2022). Potentially inappropriate medication use in patients with dementia. International Journal of Environmental Research and Public Health, 19 (18), 11426.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Camile Camargo; Fabiana da Silva Santos; Clarissa Vasconcelos de Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
